60 Degrees Pharmaceuticals Signs Patent License Deal to Develop Tafenoquine for Tick-Borne Disease Treatment

MT Newswires Live

Apr 08, 2025

60 Degrees Pharmaceuticals (SXTP) said Tuesday it signed a patent license deal with Yale School of Medicine and Yale School of Public Health to jointly develop and commercialize Tafenoquine for the treatment and prevention of tick-borne disease babesiosis.

The deal comes after the start of collaboration between researchers from the organizations to look into the activity of tafenoquine against babesiosis, which is caused by microscopic parasites that infect red blood cells, the company said.

Tafenoquine currently doesn't have US Food and Drug Administration approval for babesiosis treatment and prevention, according to the company.

Shares of 60 Degrees Pharmaceuticals rose 83% in recent trading.

Price: 3.43, Change: +1.64, Percent Change: +91.68

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2525135808"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525135808\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2525135808?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-08 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525135808","market":"nz","top_or_hot":-1,"title":"60 Degrees Pharmaceuticals Signs Patent License Deal to Develop Tafenoquine for Tick-Borne Disease Treatment","media":"MT Newswires Live","content":"<html><body><p> 60 Degrees Pharmaceuticals (SXTP) said Tuesday it signed a patent license deal with Yale School of Medicine and Yale School of Public Health to jointly develop and commercialize Tafenoquine for the treatment and prevention of tick-borne disease babesiosis.</p><p>The deal comes after the start of collaboration between researchers from the organizations to look into the activity of tafenoquine against babesiosis, which is caused by microscopic parasites that infect red blood cells, the company said.</p><p>Tafenoquine currently doesn't have US Food and Drug Administration approval for babesiosis treatment and prevention, according to the company.</p><p>Shares of 60 Degrees Pharmaceuticals rose 83% in recent trading.</p><p>Price: 3.43, Change: +1.64, Percent Change: +91.68</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>60 Degrees Pharmaceuticals Signs Patent License Deal to Develop Tafenoquine for Tick-Borne Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n60 Degrees Pharmaceuticals Signs Patent License Deal to Develop Tafenoquine for Tick-Borne Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-08 21:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> 60 Degrees Pharmaceuticals (SXTP) said Tuesday it signed a patent license deal with Yale School of Medicine and Yale School of Public Health to jointly develop and commercialize Tafenoquine for the treatment and prevention of tick-borne disease babesiosis.</p><p>The deal comes after the start of collaboration between researchers from the organizations to look into the activity of tafenoquine against babesiosis, which is caused by microscopic parasites that infect red blood cells, the company said.</p><p>Tafenoquine currently doesn't have US Food and Drug Administration approval for babesiosis treatment and prevention, according to the company.</p><p>Shares of 60 Degrees Pharmaceuticals rose 83% in recent trading.</p><p>Price: 3.43, Change: +1.64, Percent Change: +91.68</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SXTP","symbol_name":"60 degrees pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2525135808","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525135808","pubTimestamp":1744120430,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"60 Degrees Pharmaceuticals  said Tuesday it signed a patent license deal with Yale School of Medicine and Yale School of Public Health to jointly develop and commercialize Tafenoquine for the treatment and prevention of tick-borne disease babesiosis.The deal comes after the start of collaboration between researchers from the organizations to look into the activity of tafenoquine against babesiosis, which is caused by microscopic parasites that infect red blood cells, the company said.Tafenoquine currently doesn't have US Food and Drug Administration approval for babesiosis treatment and prevention, according to the company.Shares of 60 Degrees Pharmaceuticals rose 83% in recent trading.Price: 3.43, Change: +1.64, Percent Change: +91.68","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SXTP":"60 degrees pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"60度制药签署专利许可协议，开发用于蜱传疾病治疗的他非诺喹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SXTP":0.9},"content_text":"60 Degrees Pharmaceuticals (SXTP) said Tuesday it signed a patent license deal with Yale School of Medicine and Yale School of Public Health to jointly develop and commercialize Tafenoquine for the treatment and prevention of tick-borne disease babesiosis.The deal comes after the start of collaboration between researchers from the organizations to look into the activity of tafenoquine against babesiosis, which is caused by microscopic parasites that infect red blood cells, the company said.Tafenoquine currently doesn't have US Food and Drug Administration approval for babesiosis treatment and prevention, according to the company.Shares of 60 Degrees Pharmaceuticals rose 83% in recent trading.Price: 3.43, Change: +1.64, Percent Change: +91.68","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}